November 17, 2016

The Food and Drug Administration has approved a generic of Mikart’s hydrocodone bitartrate and acetaminophen tablets from Gavis Pharmaceuticals, Lupin’s U.S. subsidiary, the company announced Thursday. 

November 17, 2016

A new survey from InCrowd found that 84% of surveyed physicians in dermatology, endocrinology, gastroenterology, oncology and rheumatology said they expect to prescribe, will prescribe or look forward to prescribing more biosimilars in the coming three years. 

November 16, 2016
The companies said their biosimilar candidate, ABP 215, is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar. 
 
November 16, 2016

Biosimilars are expected to save the healthcare system between $44 billion and $250 billion in the next 10 years.

November 16, 2016

Aurobindo has introduced a new label design as the company continues to eclipse market growth predictions, most recently moving into the Top 6 among all generic companies in prescriptions dispensed, according to QuintilesIMS National Prescription Audit data from August.

November 16, 2016

The Generic Drug User Fee Agreement, enacted under the Food and Drug Administration Safety and Innovation Act of 2012, has generated some $1.5 billion in user fees and has seen 1,992 approvals issued.

November 16, 2016

Generic medications saved the U.S. healthcare system more money in 2015 than ever before, according to the eighth-annual “2016 Generic Drug Savings & Access in the United States Report,” compiled by Quintiles IMS Institute on behalf of the Generic Pharmaceutical Association. This year’s report found $227 billion saved by using generics in 2015.

November 15, 2016

The Washington Post is reporting that President-elect Donald Trump’s transition website may be hinting to drug and medical device makers that under his administration, it might be easier to get their treatments to patients. 

November 11, 2016

The Dr. Reddy’s generic will be available in 30-, 100- and 1,000-count bottles of 60-mg dosage strength tablets.

November 11, 2016

President-elect Donald Trump on Friday softened his stance on his manifesto to "repeal and replace" the Affordable Care Act, The Wall Street Journal reported. Following his meeting with President Barack Obama, Trump suggested he may keep a few provisions, such as the ban on denying insurance based on pre-existing conditions and the provision allowing parents to extend coverage for their children. "I told [Pres. Obama] I will look at his suggestions, and out of respect, I will do that,” Trump told The Journal. “Either Obamacare will be amended, or repealed and replaced.” (The Wall Street Journal)

November 10, 2016

An HDA survey found that a majority of pharmaceutical manufacturers, 89%, indicated that distributors will start to receive serialized products before the DSCSA-mandated deadline.

November 10, 2016
The consortium said the redesign is part of its digital evolution to showcase its industry expertise and support its overall growth. 
November 9, 2016
Business Insider is reporting that as news that Donald Trump will be the 45th president sent stocks into an early Thursday tumble in Europe, by around 9:50 a.m. in London (4:50 a.m. EST), pharmaceutical stocks were rising, with Hikma Pharmaceuticals’s stock up 6% on the FTSE 100. Roche and Novartis saw stock increases over 4% and GSK saw a 1.8% bump. Jefferies pointed to hope that efforts to enact new pricing rules on drugs led the swell, telling Business Insider, “Sentiment towards the Healthcare sector ought to swing initially away from draconian fears over drug pricing.” (Business Insider)
 
 
November 8, 2016

The companies believe their submission has the potential to be the first of a proposed biosimilar for the drug in the United States. 

November 7, 2016
Ajanta’s generic will be available in 50- and 200-mg dosage strengths. 
November 7, 2016

Endo has announced the appointment of two key executive leadership team members, naming Terrance J. Coughlin its EVP and COO, and adding Tony Pera as the president of Endo’s U.S. generics company Par Pharmaceutical. 

November 7, 2016

The company will collaborate with Bluepharma to develop and distribute a generic product in a category with U.S. sales more than $75 million, according to QuintilesIMS data for the 12 months ended July 2016. 

November 7, 2016

Teva has gotten approval from the Food and Drug Administration for two generics of high blood pressure drugs, one of which it has launched. 

November 4, 2016

Camber Pharmaceuticals on Thursday announced the launch of its generics of Avodart (dutasteride) capsules and Levaquin (levofloxacin) tablets.

November 2, 2016

Ajanta has launched its generic of Azor, a high blood pressure treatment. 

November 2, 2016
The contraceptive had U.S. sales of $178.2 million for the 12 months ended June 2016, according to QuintilesIMS data. 
November 1, 2016

The drug  had U.S. sales of $911 million for the 12 months ended September 2016, according to QuintilesIMS data.

October 31, 2016

Under the agreement, AstraZeneca will continue to manufacture and supply the drug and its authorized generic to Aralex Ireland for at least 10 years, and it will continue to distribute the product until it is transferred, which could be up to nine months after closing. 

October 31, 2016

Camber Pharmaceuticals on Monday announced the launch of its Crestor (rosuvastatin) generic. The drug is indicated to treat high triglycerides and cholesterol.